Background {#Sec1}
==========

Postpartum haemorrhage (PPH) is a major cause of maternal mortality and morbidity worldwide \[[@CR1]--[@CR4]\]. Approximately 36% of all lower segment cesarean deliveries and between 6 and 14% of spontaneous deliveries are complicated by PPH, depending on the definition used and the population studied \[[@CR5]--[@CR7]\]. Although global mortality from PPH is falling, its incidence is increasing in several high resource settings \[[@CR8], [@CR9]\]. In the United States, between 1994 and 2006, the rate of atonic PPH increased by 160% among women undergoing cesarean section after induction of labour and 130% among women undergoing non-induced cesarean section \[[@CR10]\]. This increase may be explained by the increasing rates of cesarean sections and associated complications caused by general anesthesia, operative techniques or complications such as placental abruption leading to an emergency cesarean section \[[@CR8], [@CR11]--[@CR14]\], but also due to an extensive use of uterotonics to induce or augment labour \[[@CR7], [@CR14]\].

The most widely used uterotonic drug for augmenting labour or to maintain uterine contractility during labour is oxytocin \[[@CR15], [@CR16]\]. Oxytocin, which was first synthetically synthesized in 1953 is also the first choice in the prevention and treatment of uterine atony \[[@CR17]\]. When given in low-dose, oxytocin induces rhythmic uterine contractions which are indistinguishable in frequency, duration and strength from contractions observed during spontaneous labour \[[@CR18], [@CR19]\]. On the other hand, oxytocin for inducing or augmenting labour may desensitise the oxytocin receptors, thereby impairing oxytocin's post-delivery effects on uterine contractility \[[@CR18]\]. For example, Balki et al. showed in different in vitro studies that pretreatment with oxytocin decreases oxytocin-induced myometrial contractions in pregnant humans and animals \[[@CR20]--[@CR22]\]. In addition, Grotegut et al. conducted a retrospective study on women who experienced severe PPH and found that these women received significantly greater amounts of oxytocin during labour compared with women without PPH, suggesting that prolonged pre- or intrapartum exposure to oxytocin might lead to decreased drug efficacy \[[@CR23]\]. Similarly, Belghiti et al. investigated in a population-based case-control study the association between the level of oxytocin exposure during labour and the risk of severe atonic PPH \[[@CR24], [@CR25]\]. The study showed that oxytocin exposure during labour appears to be an independent risk factor for severe PPH in woman with spontaneous labour who did not receive prophylactic oxytocin after delivery (odds ratio after adjustment for all potential confounders \[adjusted OR\]: 1.8, 95% CI 1.3 to 2.6). Thereby, the strength of the association increased with the amount of oxytocin infused during labour \[[@CR24], [@CR25]\].

Considering that PPH rates are higher in cesarean section compared to spontaneous labour \[[@CR7]\], particularly labouring women requiring cesarean delivery may constitute a subset of patients that may exhibit a negative response to exogenous oxytocin \[[@CR14]--[@CR16]\]. Therefore, we mapped the current literature for controlled clinical studies investigating the risk of atonic PPH in labouring women requiring cesarean delivery (intrapartum cesarean section) after oxytocin use for labour induction or augmentation in comparison to no exogenous oxytocin.

Methods {#Sec2}
=======

Sources {#Sec3}
-------

We adhered to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) protocol for identifying, screening and eligibility of studies to conduct the present research work \[see Additional file [1](#MOESM1){ref-type="media"}\].

We searched for controlled clinical studies investigating exogenous oxytocin in cesarean delivery, irrespective of delivery indication, age, comorbidity or woman's parity. Primary maternal outcomes, we were interested in, included PPH rates, adverse effects or the need for additional uterotonics. In addition we collated any neonatal outcomes reported. A review protocol can be accessed from the corresponding author (CS).

Published studies were identified from searches of electronic databases. We searched Medline (OvidSP), Embase, Web of Science, the Cochrane library from inception until May 2016. The search strategy was based on combinations of medical subject headings (MeSH) and keywords and was not restricted to specific languages. The search strategy used in Medline (OvidSP) is presented in an additional file \[see Additional file [2](#MOESM2){ref-type="media"}\]. Search strategies for other databases were modified to meet the requirements of each database. The searches were supplemented by screening the bibliographies of relevant studies and systematic reviews. Potential ongoing studies were identified in the International Clinical Trials Registry Platform WHO ([http://www.who.int/ictrp/en/](http://www.who.int/ictrp/en)) and the Register for Clinical Trials (<http://clinicaltrials.gov>/).

Study selection {#Sec4}
---------------

One author (KB) screened the titles and abstracts of all reports identified by electronic searches. We obtained full-text copies of all potentially relevant articles and 2 reviewers (KB, CS) assessed them for inclusion. These authors also independently carried out data extraction for key characteristics of the study, participant and intervention.

Data analysis (mapping the evidence) {#Sec5}
------------------------------------

First, study characteristics such as country, study design, details of the intervention and control intervention, time point of drug application, week of gestation, sample size, age and indication for cesarean section were extracted and tabulated. Second, we looked whether the given PPH rates were stratified after the indication for cesarean delivery and/or when only women with intrapartum cesarean section were included whether the results were stratified after the use of oxytocin versus no oxytocin before surgery. By considering key characteristics of all studies investigating oxytocin in cesarean section, evidence gaps for a subset of women could be identified and a narrative description of the current literature provided.

Results {#Sec6}
=======

Published studies {#Sec7}
-----------------

We identified 7866 titles and abstracts; for 432 of these, the full text was evaluated. Figure [1](#Fig1){ref-type="fig"} outlines the screening and selection process of the articles. Table [1](#Tab1){ref-type="table"} presents the key characteristics of the 36 controlled trials investigating the risk of PPH after the use of exogenous oxytocin in cesarean section: 23 randomized controlled trials (RCTs) (including 4084 patients), 2 comparative dose-response studies (including 100 patients) and 11 non-RCTs (including 3896 patients).Fig. 1PRISMA flow diagram: Results of the bibliographic literature search in Medline, Embase, Web of Science, and the Cochrane Library in May 2016 (as published by *Moher D* et al. *in BMJ 2009;339:b2535*). RCT: randomized controlled trial Table 1Studies Included in Scoping ReviewStudy & CountryStudy typeIntervention (I1) & Control (I2)Time point of drug applicationPopulationFollow-up & beginning and end of studyWeek of gestation\
(mean ± SD)Women\
(n)Age\
(mean ± SD;\
median \[range\])IndicationComparative dose-response studiesBalki 2006 \[26\]\
CanadaRCT"the dose of oxytocin for each patient was determined by the response of the previous patient (±0,5 IU) to the drug, according to a biased coin up- and-down sequential allocation scheme to cluster doses close to the minimum effective dose (ED~90~)"^a^"immediately upon delivery of the anterior shoulder of the infant"39.9 ± 1.1total: 3032.7 ± 4.4CS for labour arrest\
"augmentation with iv oxytocin for a minimum of 2 h"48 h\
03/04--12/04Lavoie 2015 \[27\]\
USRCT"dose-response study using a 9:1 biased-coin sequential allocation method to estimate the ED~90~ of an infusion of prophylactic oxytocin in women undergoing CS with neuraxial anesthesia. The starting infusion rate was 18 IU/h, with an incremental dose of 2 IU/h.""immediately after the umbilical cord was clamped"I1: 40 (40--41)\
I2: 39 (39--39)I1: 32\
I2: 38I1: 33 (28--35)\
I2: 33 (31--36)I1:"labouring group: women scheduled for intrapartum CS after prior exposure to exogenous oxytocin"^b^\
I2:"non-labouring group: women scheduled for CS"24 h\
08/12--06/13Different Oxytocin dosesMunn 2001 \[28\]\
USRCTI1: Oxytocin 10 IU, *iv*, 30 min\
I2: Oxytocin 80 IU, *iv*, 30 min\
+prn Oxytocin for labour induction;^c^ after delivery in the postanesthesia care unit, all patients received oxytocin, 20 IU, *iv*, 8 h"after cord clamping"I1: 37 ± 4.3\
I2: 37 ± 4.9I1: 163\
I2: 158I1: 25 ± 6.0\
I2: 25 ± 6.1labour before CS^d^1 day\
01/97--11/99Ayedi 2011 \[55\]\
TunisiaRCTI1: Oxytocin 2 IU (in 5 ml volume), *iv,* single-dose, 5--10 s\
I2: Oxytocin 5 IU (in 5 ml volume), *iv,* single-dose, 5--10 s\
+prn uterotonics"after delivery of the baby and cord clamping"≥37total: 60------Chou 2015 \[56\]\
MalaysiaRCTI1: Oxytocin 40 IU (in 500 ml NaCl), *iv,* over 6 h\
I2: Oxytocin 80 IU (in 500 ml NaCl), *iv,* over 6 h\
+all P. were given an oxytocin bolus of 5 IU"post-delivery"---------\
11/12--05/13Khan 2012 \[32\]\
IndiaRCTI1: Oxytocin 10 IU (in 500 ml NaCl), *iv,* over 1 h\
I2: Oxytocin 20 IU (in 500 ml NaCl), *iv,* over 1 h\
+prn uterotonics----total: 200--emergency24 h\
study duration: 6 mosKintu 2012 \[54\]\
UgandaRCTI1: Oxytocin 2.5 IU, no further information\
I2: Oxytocin 10 IU, no further information\
+prn uterotonics"following cord clamping"--total: 380--emergency and elective24 h\
-Lee 2014 \[48\]\
USNon-RCT\
(retrospective)I1: Oxytocin 10 IU, *iv* Infusion was continued until P. transfer to the recovery room\
I2: Oxytocin 30 IU, *iv,* over 1 h"following cord clamping"--I1: 483\
I2: 418I1: 32 ± 6\
I2: 33 ± 6---\
I1: 09/08--11/08\
I2: 11/08--01/09Pursche 2012 \[42\]\
GermanyNon-RCT\
(retrospective)I1: Oxytocin 3 IU, *iv*, single-dose + continuously 3 IU oxytocin, *iv*, infusion rate 100 ml/h\
I2: Oxytocin continuously 3 IU oxytocin, *iv*, infusion rate at least 120 ml/h"postpartum"I1: 37.9\
I2: 37.9I1: 228\
I2: 227--elective (*n* = 71) and during labour (*n* = 384)^e^4 h\
01/11--12/11McClune 2011 \[44\]\
UKNon-RCT\
(retrospective)Different doses oxytocin, not administered uniformly^f^\
+ prn uterotonics"given at cord clamping"--total: 50-----\
08/10--09/10Application schemaMangla 2012 \[59\]\
IndiaRCTI1: Oxytocin 20 IU, *iv*\
I2: Oxytocin 5 IU, *imy*\
I3: Oxytocin 5 IU, *imy*\
No information about additional uterotonicsI1 + I2: "after separation of placenta"\
I3: "before separation of placenta"--I1: 50\
I2: 50\
I3: 50----1 h\
-Oxytocin vs other uterotonics time-dependentAdefuye 2012 \[50\]\
NigeriaRCTI1: Oxytocin 20 IU, *iv*\
I2: Misoprostol 2 × 400 μg, *sublingual*\
+prn uterotonics intraopI1: "after delivery"\
I2: "before delivery"I1: 38.0 ± 0.2\
I2: 38.1 ± 0.3I1: 50\
I2: 50I1: 28.7 ± 0.7\
I2: 29.9 ± 0.8elective (28%) and emergency (72%)^g^24 h\
04/09--03/11Chaudhuri 2010 \[60\]\
IndiaRCTI1: Oxytocin 8 × 5 IU, *iv* + placebo, *rectal*\
I2: Misoprostol 4 × 200 μg, *rectal* + 8 placebo, *iv*\
+prn uterotonicsI1: "after delivery"\
I2: "before incision"I1: 39.2 ± 1.4\
I2: 39.5 ± 1.7I1: 100\
I2: 100I1: 24.3 ± 5.0\
I2: 24.0 ± 3.4elective and emergency^h^\
without risk factors for PPH24 h\
12/07--06/09Oxytocin vs placeboKing 2010 \[49\]\
CanadaRCTI1: Oxytocin 5 IU, *iv*, über 30 s, single-dose\
I2: Placebo NaCl, *iv*, 30 s, single-dose\
+routinely oxytocin (40 IU, *iv*, 30 min) followed by oxytocin (20 IU) immediately after study drug\
+prn uterotonics"as soon as the umbilical cord was clamped"I1: 37.0 ± 3.0\
I2: 38.0 ± 2.0I1: 75\
I2: 75I1: 34 ± 5\
I2: 34 ± 6elective (*n* = 76) and non-elective (*n* = 67)\
at least one risk factor for PPH24 h\
11/05--10/06Oxytocin vs other uterotonicsAttilakos 2010 \[34\]\
UKRCTI1: Oxytocin 5 IU, *iv*, 30--60 s\
I2: Carbetocin 100 μg, *iv*, 30--60 s\
+prn uterotonics (Oxytocin for PPH prophylaxis or treatment)"after the birth of the baby"≥37I1: 189\
I2: 188I1: 32 (18--44)\
I2: 32 (18--42)elective (60%) and emergency (40%)\
1/3 showed risk factors for PPHuntil discharged\
11/06--07/07Borruto 2009 \[35\]\
ItalyRCTI1: Oxytocin 10 IU, *iv*, 2 h\
I2: Carbetocin 100 μg, *iv*, single-dose\
+prn uterotonics"immediately following placental delivery"≥36I1: 52\
I2: 5232.2 (22--41)planned and emergency^i^\
at least one risk factor for PPH24 h\
09/07--01/08Catanzarite 1990 \[47\]\
USRCTI1: Oxytocin 20 IU, *imy*\
I2: Carboprost tromethamine 125 μg, *imy*\
+routinely oxytocin (20 IU, *iv*) after placental delivery"immediately following placental delivery"--I1: 21\
I2: 25I1: 24.5\
I2: 24.1planned and emergency^j^3 days\
-Chaudhuri 2014 \[33\]\
IndiaRCTI1: Oxytocin 8 × 5 IU, *iv*, 12 h + placebo *rectal*\
I2: Misoprostol 4 × 200 μg, *rectal* + placebo *iv*, 12 h\
+routinely oxytocin, not later than 1 min after delivery"at the end of the operation"I1: 38.8 ± 1.2\
I2: 39.0 ± 1.1I1: 96\
I2: 96I1: 23.2 ± 3.7\
I2: 23.5 ± 4.5emergency\
without risk factor for PPH24 h\
05/11--05/12Lapaire 2006 \[36\]\
SwitzerlandRCTI1: Oxytocin 20 IU, *iv*, 8 h + placebo *oral*\
I2: Misoprostol 800 μg, *oral* + placebo *iv*, 8 h\
+routinely oxytocin (5 IU, *iv*) after cord clamping"immediately after cord clamping"I1: 38.7 ± 1.3\
I2: 38.6 ± 1.3I1: 28\
I2: 28I1: 31.2 ± 5.1\
I2: 32.2 ± 6.5elective and indicated^k^\
low risk for PPH48 h\
01/99--02/02Lokugamage 2001 \[37\]\
UKRCTI1: Oxytocin 10 IU, *iv*, single-dose + placebo, *oral*\
I2: Misoprostol 500 μg, *oral* + placebo *iv*, single-dose\
+prn uterotonics"immediately after the delivery of the baby"I1: 38.3 ± 1.1\
I2: 36.7 ± 8.9I1: 20\
I2: 20I1: 31.4 ± 5.5\
I2: 32.3 ± 6.4elective (n = 38) and emergency (*n* = 2)\
excluded: previous rupture of the uterus3 days\
-Owonikoko 2011 \[51\]\
NigeriaRCTI1: Oxytocin 20 IU, *iv*\
I2: Misoprostol 400 μg, *sublingual*\
+prn Oxytocin *iv*"immediately after extraction of the baby"I1: 39.7 ± 1.9\
I2: 38.7 ± 2.3I1: 50\
I2: 50I1: 30.4 ± 4.8\
I2: 31.5 ± 4.1elective (35%)^l^ and emergency (65%)^m^24 h\
06/06--04/07Razali 2016 \[30\]\
MalaysiaRCTI1: Oxytocin 10 IU, *iv*, single-dose\
I2: Carbetocin 100 μg, *iv*, single-dose\
+prn uterotonics"after delivery""at term"I1: 300\
I2: 300I1: 29.7 ± 4.3\
I2: 29.5 ± 4.6emergency^n^24 h\
14/08--09/12Vimala 2006 \[61\]\
IndiaRCTI1: Oxytocin 20 IU, *iv*, 6 h\
I2: Mis\
+prn uterotonics"immediatiely after delivery of the neonate"I1: 38.7 ± 1.1\
I2: 38.7 ± 1.2I1: 50\
I2: 50I1: 26.3 ± 3.7\
I2: 25.6 ± 5.1elective (17%) and emergency (83%)^o^\
without risk factors for PPH24 h\
08/04--04/05El Behery 2016 \[29\]\
EgyptRCTI1: Oxytocin 20 IU, *iv*\
I2: Carbetocin 100 μg, *iv*, 2 min\
+prn uterotonics"after delivery of the infant preferably before placental removal"I1: 38.2 ± 0.8\
I2: 38.2 ± 1.2I1: 90\
I2: 90I1: *n* = 90\
I2: n = 90emergency24 h\
01/13--06/14Whigham 2016 \[31\]\
AustraliaRCTI1: Oxytocin 5 IU, *iv*\
I2: Carbetocin 100 μg, *iv*\
+prn uterotonics"immediately after birth of the baby"I1: 40.0 ± 1.4\
I2: 39.6 ± 1.5I1: 53\
I2: 59I1: 28.9 ± 5.8\
I2: 28.3 ± 5.9non-elective and emergency^p^-\
08/12--02/13Alli 2013 \[53\]\
NigeriaRCTI1: Oxytocin 10 IU, *iv,* single-dose\
I2: Misoprostol 600 μg, *sublingual*\
+prn uterotonics"immediately after delivery of the baby"--total: 100------Begum 2015 \[57\]\
BangladeshRCTI1: Oxytocin 20 IU (in 100 ml Dextrose NaCl), *iv*\
I2: Misoprostol 400 μg, *sublingual*\
+prn uterotonics"soon after delivery""term pregnancy"total: 100------Pizzagalli 2015 \[41\]\
FranceNon-RCT\
(prospective)I1: Oxytocin 5 IU *iv*, followed by 10 IU *iv* during surgery, further infusions 10 IU 8 h postop\
I2: Carbetocin 100 μg *iv*\
I3: Oxytocin 5 IU *iv*, followed by 10 IU *iv* during surgery, further infusions 10 IU 8 h + Sulprostone"during cord clamping"≥37I1: 282\
I2: 262\
I3: 258--CS before labour (*n* = 283) and unclear indication (*n* = 519)24 h\
I1: 07/10--12/10\
I2: 02/11--12/11\
I3: 08/11--01/12Triopon 2010 \[62\]\
FranceNon-RCT\
(retrospective)I1: Carbetocin 100 μg, *iv*\
I2: Oxytocin 5 IU, *iv*"after cord clamping"I1: 38.2 ± 3.0\
I2: 37.9 ± 3.2I1: 155\
I2: 155I1: 30.6 ± 5.3\
I2: 30.7 ± 5.4elective and during labour24 h\
I1: 04/09--07/09\
I2: 03/07--06/07Demetz 2013 \[46\]\
FranceNon-RCT\
(retrospective)I1: Oxytocin 10 IU, *iv*, single-dose^q^\
+3 h after delivery: 10 IU Oxytocin *iv* over 12 h\
I2: Carbetocin 100 μg, *iv*, single-dose\
+3 h after delivery: 10 IU Oxytocin *iv* over 12 h"at the delivery"I1: 35.5 ± 2.5\
I2: 34.3 ± 3.1I1: 24\
I2: 39I1: 31.6 ± 4.3\
I2: 31.1 ± 5.8planned (*n* = 31) and unclear (*n* = 32)48 h\
I1: 08/09--01/10\
I2: 02/10--07/10Testa 2013 \[45\]\
ItalyNon-RCT\
(retrospective)I1: Oxytocin 10 IU, *iv*, 2 h\
I2: Carbetocin 100 μg, *iv*, single-dose----I1: 14\
I2: 14--planned and emergency24 h after drug application\
-Brzozowska 2015 \[63\]\
PolskaNon-RCT\
(retrospective)I1: Oxytocin 10 IU, *im*\
I2: Carbetocin 100 μg, *iv*\
+prn uterotonics--I1: 38.3 ± 1.9\
I2: 38.1 ± 1.9I1: 140\
I2: 139I1: 30.5 ± 4.6\
I2: 31.5 ± 5.1---\
03/14--10/14Combination therapyKoen 2016 \[52\]\
South AfricaRCTI1: Oxytocin 2,5 IU, *iv*, single-dose + placebo *im*\
I2: Oxytocin + Ergometrine Placebo *iv* + Oxytocin 5 IU, *im* + Ergometrine 0.5 mg, *im*\
+routinely 10 IU Oxytocin"after delivery of the neonate"I1: 38.4 ± 2.2\
I2: 38.5 ± 1.9I1: 214\
I2: 202I1: 28.6 ± 6.0\
I2: 28.9 ± 5.4elective (36%) and emergency (64%)^r^6--24 h\
01/4--06/14Mahmud 2014 \[58\]\
PakistanNon-RCT\
(prospective)I1: Oxytocin 10 IU *iv*\
I2: Oxytocin 10 IU *iv* + Ergometrine 0,25 mg *im*"intraoperatively"I1: 37.5 ± 2.0\
I2: 38.0 ± 1.8I1: 378\
I2: 323I1: 28.0 ± 3.5\
I2: 29.0 ± 3.4elective and emergency6 h\
I1: 11/10--12/10\
I2: 01/11--02/11Bayoumeu 2003 \[38\]\
FranceNon-RCT\
(retrospective)I1: Oxytocin 5 IU *iv (single dose)*, 10 IU *iv* 30 min, afterwards 25 IU *iv* 24 h\
I2: Oxytocin 5 IU *iv (single dose)*, 10 IU *iv* 30 min, afterwards 25 IU *iv* 24 h + Dinoprost/Sulprostone"after clamping the last umbilical cord"I1: 32.0 ± 2.7\
I2: 32.8 ± 1.7I1: 14\
I2: 28I1: 29.1 ± 3.2\
I2: 30.2 ± 3.3elective and emergency48 h\
I1: 01/93--11/96\
I2: 12/96--12/00Lourens 2007 \[40\]\
UKNon-RCT\
(prospective)I1: Oxytocin 5 IU iv, single-dose\
I2: Oxytocin 5 IU *iv*, single-dose + Ergometrine 0.5 mg *im*Oxytocin: "after delivery"\
Ergometrine: "during abdominal closure"I1: 38.0 ± 1.0\
I2: 38.0 ± 1.0I1: 158\
I2: 107--elective (*n* = 120) and emergency (*n* = 145)-\
I1: 02/06--03/06\
I2: 04/06--06/06^a^The dose of oxytocin for each woman was determined by the response of the previous woman to the drug, (...). If a woman did not respond adequately to the initial bolus of oxytocin, the initial dose for the next one was increased by 0.5 IU. If the woman responded to the initial bolus, the dose for the next one was decreased by 0.5 IU with a probability of 1/9; otherwise it remained unchanged. (...) . The starting dose of oxytocin was arbitrarily chosen as 0.5 IU^b^CS due to labour dystocia, defined as arrest of dilation in first stage of labour or arrest of descent in second stage of labour^c^Results were not reported separately for women with or without prepartal oxytocin administration^d^Labour was defined as at least two contractions in 10 min and either an initial cervical dilation of at least 2 cm or progressive cervical change. Indications: non-reassuring FHR tracing (58%), arrest of labour (75%), abnormal lie (44%), other reasons (24%)^e^Cardiotocography abnormalities (92), breech presentation (67), macrosomia (19), preeclampsie/HELLP (14), state after recesarean (22), twins/triplets (24/2), obstructed labour (29), fetal abnormalities/disease (22), maternale disease (54), placenta praevia/ bleeding (21)^f^Initial bolus dose of oxytocin given at cord clamping and any subsequent bolus doses were recorded along with the concentration and rate of the maintenance oxytocin infusion if used and any other uterotonic drugs^g^Indications: severe pregnancy induced hypertension/hypertensive disorders (20), uncontrolled diabetes mellitus (1), precious baby (bad obstetric history/pregnancy after infertility treatment) (2), fetal distress (33), abnormal lie (transverse/oblique lie) (3), malpresentation (face/brow) (5), dystocia (foeto-pelvic disproportion/occipito-posterior/transverse arrest) (23), macrosomia (3), breech (6), prolonged pregnancy (4)^h^Indications: previous cs (51), prolonged pregnancy (failed induction) (23), malpresentation (10), preeclampsie (11), PROM (9), cephalopelvic disproportion (14), fetal distress (27), non-progress of labour (19), poor obstetric history (6), IUGR/oligohydramnios (7), elderly primigravida/infertility treated (13)^i^Indications: previous cs (28), abnormal presentation (24), dystocia (18), FHR anomalies (16), umbilical cord prolapse (2), feto-pelvic disproportion (2), IUGR (2), fetal megalosomy (2), abruptio placentae (2), placenta previa (2), maternal disease (2), failed induction of labour (2), maternal request (2)^j^Indications: elective, prior to labour (35), early labour (7), cephalopelvic disproportion (4)^k^Indications: elective cs or breech presentation (31), malposition (1), twin pregnancy (1), repeated cs (5), ineffective induction of labour (2), ineffective induction of labour and infection (1), failure of labour to progress (1), hip dysplasia (1), IUGR (2), ankylosing spondylitis (1), macrosomia (2), placenta previa (2), Increased pressure not indicated (retinal disease, colposuspension) (3)^l^Indication for elective cs: maternal, medical condition (HIV, herpes) (4), two previous cs (9), malpresentation (transverse lie, breech in primigravidae etc.) (6), maternal request for cs (4), fetal macrosomia (12)^m^Indication for emergency: fetal distress (14), cephalopelvic disproportion (9), malpresentation in labour (9), failed vaginal birth after cs (20), failed induction of labour (4), severe oligohydramnios (9)^n^Indication for emergency: defined as an unplanned procedure performed after the start of labour and labour as regular contractions at least every 10 min and cervical dilatation \>3 cm; non reassuring fetal status (267), failure to progress in labour (189), malpresentation (34), prolonged second stage (15), other reasons (42)^o^Indication: fetal breech presentation (14), cephalopelvic disproportion (10), nonprogress of labour (16), meconium stained liquor (25), fetal variable decelerations (20), scar tenderness (2), transverse lie (3), Type II decelerations (5), prolonged latent phase (2), previous lower segment cs with unfavorable cervix(3)^p^Women with planned labour induction, were in early labour or were in active labour but had an epidural anaesthetic. Results were not reported separately for women with or without prepartal oxytocin administration^q^In case of PPH, French national guidelines were applied^r^Indications: previous CS (188), fetal distress (87), cephalopelvic disproportion (41), poor progress (30), failed induction of labour (14), breech (14), twins (11), other reasons (24)CS: cesarean section; dl: decilitre; ED: effective dose; FHR: fetal heart rate; g: gram; GA: gestational age; h: hours; I1: intervention; I2: control intervention; im: intramuscular; imy: intramyometrial; intraop: intraoperatively; IUGR: intrauterine growth retardation; IU: international units; iv: intravenous; mg: milligram; min: minutes; ml: milliliter; mU: milliunit; n: number; NaCl: saline; non-RCT: non-randomized controlled trial; P: participants; postop: postoperatively; PPH: postpartum hemorrhage; prn: pro re nata; PROM: premature rupture of membranes; RCT: randomized controlled trial; s: seconds; SE: standard error; UK: United Kingdom; US: United States; μg: microgram; vs: versus

Intrapartum cesarean delivery {#Sec8}
-----------------------------

From 36 studies identified, 8 studies (1705 patients) included solely women requiring intrapartum cesarean delivery, mainly because of labour arrest \[[@CR26]--[@CR33]\]. However, from these 8 studies, only 2 dose-response studies addressed the hypothesis whether parturients who receive intrapartum exogenous ocytocin are prone to a higher risk of PPH by evaluating uterine contraction after delivery \[[@CR26], [@CR27]\]: *(i)* Thereby, the dose-response study from Lavoie et al. investigated whether women who receive intrapartum exogenous oxytocin, and who subsequently undergo cesarean delivery for labour dystocia, need a higher estimated effective dose of oxytocin in 90% of women (ED90) compared with non-labouring parturients \[[@CR27]\]. Thirty-two women participated in the labouring and 38 women in the non-labouring group. The reported oxytocin ED90 was significantly greater for the labouring group requiring cesarean delivery compared with that for the non-labouring group (mean difference: 28 Units/h \[95% CI 26--29 Units/h, *P* \< 0.001\]). Furthermore, significantly more women in the labouring group compared to the non-labouring group required additional uterotonic agents (mean difference: 26% \[95% CI 7--44%, *P* = 0.008\]). *(ii)* The other dose-response study from Balki et al. estimated the minimum effective intravenous dose of oxytocin required for adequate uterine contraction after cesarean delivery for labour arrest, however, without using an active control group \[[@CR26]\]. In this study, all 30 patients received oxytocin infusion at a mean of 9.8 ± 6.3 h before cesarean delivery. After delivery, oxytocin was administered as a slow intravenous bolus according to a coin up-down sequential allocation scheme. The minimum oxytocin ED90 required to produce adequate uterine response was estimated to be 3.0 U (95% CI 2.3--3.7 U). The authors concluded that women with intrapartum cesarean section for labour arrest require an oxytocin dose that is 9 times higher than previously reported after elective cesarean section in non-labouring women at term. However, the results of these dose-response studies are limited by comparing different patient populations without controlling for potential confounders such as women with increased risk of uterine atony, age, anticoagulant medication, general anaesthesia or multiple pregnancy. In addition, the authors used 'satisfactory uterine contraction' assessed by palpating the uterus as main outcome. Beside the fact that this outcome is subjective and not validated to estimate the effect of oxytocin on the uterus, it can not be excluded that due to a lack of blinding of the obstetricians, different thresholds for satisfactory uterine tone in women with prior labour compared with non-labouring women were used. Therefore, theses study results need to be interpreted with caution. The remaining 6 studies including women with intrapartum cesarean sections investigated different doses or application schedules of exogenous oxytocin or compared oxytocin to other uteronotics after cesarean delivery for PPH prophylaxis \[[@CR28]--[@CR32]\]. Whether the prepartal oxytocin status is a risk factor for atonic PPH could not be derived from these studies.

Intrapartum and prelabour cesarean delivery {#Sec9}
-------------------------------------------

Our mapping also revealed that the majority of studies investigating PPH rates for different treatment groups are focused on prophylactic uterogenics and included women with different types of cesarean delivery (intrapartum and prelabour cesarean section). However, the PPH rates given in these studies were not stratified according to the indications for cesarean section. In addition, the prepartal oxytocin status was not considered as confounding factor by conducting subgroup analyses \[[@CR34]--[@CR63]\].

Ongoing studies {#Sec10}
---------------

The search for ongoing and unpublished studies identified 2 RCTs which may provide subgroup data estimating the blood loss and risk for PPH after cesarean section for labour arrest ([ClinicalTrials.gov](http://clinicaltrials.gov) Identifier: NCT01869556 and NCT02794779). The estimated completion date for both studies is by the end of 2017. In addition, we identified HOLDS, a multicentre, double-blind randomised controlled trial to compare standard and high dose regimens of oxytocin for women with confirmed delay in the first stage of labour (<http://www.isrctn.com/ISRCTN99841044>). This trial randomises 1500 women and measure differences in rates and complications associated with cesarean section. If this study provides a subgroup analysis of PPH rates in those women requiring cesarean sections, important insights addressing the present research question will be given.

Discussion {#Sec11}
==========

Current clinical practice guidelines for third stage oxytocin administration do not distinguish between women with prior oxytocin exposure and those without \[[@CR64], [@CR65]\]. This practice is also reflected by the current research in cesarean delivery, which showed that the majority of studies investigating oxytocin focus on prophylactic administration in the third stage of labour, without differing between the indications for cesarean section and, hence the prepartal oxytocin status (particularly when labour was induced or augmented). However, taking into account that labouring women requiring cesarean delivery constitute a relevant subset of patients - for whom originally spontaneous labour was anticipated - the lack of studies solely investigating this patient population is not surprising.

In total, our evidence map revealed that only 2 studies investigated the required oxytocin dose to prevent uterine atony after cesarean delivery for labour arrest. These dose-response studies support the hypothesis that labouring women exposed to exogenous oxytocin require a higher oxytocin dose after delivery than non-labouring women to prevent uterine atony after cesarean section. This finding is in accordance with the observations during spontaneous labour \[[@CR24], [@CR25]\]. However, the studies investigating this hypothesis in intrapartum cesarean delivery are all flawed by limitations of the study design as well as the outcome selection. Thus, the estimated oxytocin ED90 may be lower in labouring women than actually reported.

A limitation of our research work is that data could not be formally synthesized due to a lack of controlled studies evaluating the impact of ante partum oxytocin use on the risk of PPH in exogenous cesarean delivery. Nevertheless, the current scoping review describes key data of published studies investigating the routine use of oxytocin in caesarean delivery in their quantity, but also reveals major research gaps in this important but underrepresented obstetric area. It is obvious that research on this topic is mainly restricted to augmentation or induction of vaginal delivery \[[@CR16], [@CR66], [@CR67]\] or the prophylactic use in the third stage of labour to prevent PPH \[[@CR15], [@CR68]\]. But such data would have been only relevant to address our research question, if they had allowed us to derive PPH rates for those women who required intrapartum cesarean delivery (e.g., data from subgroup analyses). A Cochrane Review from 2013 investigated o[xytocin augmentation of labour in women with epidural analgesia for reducing operative deliveries](http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009241.pub3/full) \[[@CR69]\]. This review provides rates for cesarean sections after oxytocin exposure in comparison to placebo, but whether there is a difference in PPH rates for women requiring cesarean section were also not provided. Taking into account that the current research does not provide us with rigorous controlled data to address our research question, access to individual and/or unpublished study data may be desirable \[[@CR70]\]. Although overall progress has been made to obtain such study data, there are still major issues related to unrestricted data access. For example, released data may be incomplete, selective or not in compliance with the results reported in the corresponding publications. Facing these issues, we did not undertake efforts to include such data in our research work.

We believe that the current scoping review is important because it reveals that published research on oxytocin is restricted to the use for inducing or augmenting labour or for PPH prophylaxis, without considering women requiring intrapartum cesarean section -- not even in subgroup analyses. Given the increasing rates in cesarean sections and labour inductions in many developed countries \[[@CR71]\], well controlled studies are needed focusing on these parturient. Taking into account that different studies suggest that induction of labour increases the risk of postpartum hemorrhage and blood transfusion \[[@CR24], [@CR71]\], caution is needed when intrapartum cesarean section is performed, particularly when labour is induced or augmented, as it may result in increased maternal morbidity.

Conclusions {#Sec12}
===========

Considering that research on the risk of PPH after oxytocin exposure is generally restricted to the use of PPH prophylaxis and vaginal births, future controlled studies should evaluate whether administration of oxytocin in cesarean delivery is associated with a higher risk of PPH taking into account that labouring and non-labouring women may show a difference response to exogenous oxytocin. In addition, these studies should control for known confounding factors associated with a higher risk of PPH such as multiple pregnancy, assisted reproductive technologies, general anaesthesia, type of uterine incision or advanced maternal age \[[@CR6], [@CR13], [@CR14], [@CR72]\]. As long as there is no evidence-based guideline available for labouring women requiring cesarean delivery, obstetricans and anaesthesiologists should always be aware of an increased risk of PPH due to prior oxytocin exposure in this patient population.
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